Assertio Holdings showed Q1 2023 net product sales increase of 18%, despite reporting a net loss due to increased expenses. Assertio's growth strategy involves expanding product range through ...

Here is how Assertio (ASRT) and Aura Biosciences, Inc. (AURA) have performed compared to their sector so far this year.

LAKE FOREST, Ill., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (ASRT) (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Assertio (ASRT) is a stock that can certainly grab the attention of many investors, ...

Company Will Report Third Quarter Results on November 10, 2025 and Expects to Update Guidance Within the Current Range at That Time LAKE FOREST, Ill., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Assertio ...

CEO Brendan O'Grady stated that "our first quarter financial results... are in line with the full-year 2025 net product sales and adjusted EBITDA expectations that were set forth during the March ...

ASSERTIO THERAPEUTICS ($ASRT) posted quarterly earnings results on Wednesday, March 12th. The company reported earnings of -$0.11 per share, missing estimates of -$0. ...

(1) Amounts related to income recognized in the period from the lapsing of the statute of limitations for employee retention tax credits. (2) Legal settlements, net of insurance proceeds, represents ...